Bone development is a multistep process that includes patterning of skeletal elements, commitment of hematopoietic and/or mesenchymental cells to chondrogenic and osteogenic lineages, and further differentiation into three specialized cell types: chondrocytes in cartilage and osteoblasts and osteoclasts in bone. Although PRL has a multitude of biological actions in addition to its role in the mammary gland, very little is known about its effect on bone. Mice carrying a germline null mutation for the PRL receptor gene have been produced in our laboratory and used to study the role of PRL in bone formation. In Ϫ/Ϫ embryos, we observed an alteration in bone development of calvaria. In adults, histomorphometric analysis showed that the absence of PRL receptors leads to a decrease in bone formation rate using double calcein labeling and a reduction of bone mineral density, measured by dual energy x-ray absorptiometry. In addition, serum estradiol, progesterone, testosterone, and PTH levels were analyzed. We also established that osteoblasts, but not osteoclasts, express PRL receptors. This suggests that an effect of PRL on osteoblasts could be required for normal bone formation and maintenance of bone mass. Thus, the PRL receptor knockout mouse model provides a new tool to investigate the involvement of PRL in bone metabolism. (Endocrinology 140: 96 -105, 1999) B ONE FORMATION occurs mostly during embryonic development and postnatal growth, but is also important in adults for subsequent bone remodeling to maintain calcium homeostasis and for adaptation to physical forces. Bone formation requires recruitment, proliferation, and differentiation of osteoprogenitor cells (1, 2). Very little is known about the putative role of PRL with respect to bone cells and bone metabolism. Lactation in humans and mammals is associated with a vitamin D-induced maternal boneresorptive state, and it has also been suggested that PRL might induce the release of a bone-resorptive agent. Many clinical studies have reported a possible role for PRL in bone during pregnancy, lactation, or hyperprolactinemia, but other hormonal parameters could also be implicated, and no definitive results have been published (3-6). A direct demonstration of PRL receptor protein expression in bone cells is lacking, and the putative role of PRL in bone remains speculative. Recently, studies on PRL receptor expression in human, mouse, and rat fetal tissues have shown expression of PRL receptor messenger RNA (mRNA) and the appearance, during early fetal development of intense PRL receptor immunoreactivity in skeletal tissues, including long bones, vertebrae, and ribs (7-9). Also, PRL receptor transcripts were detected in two human osteoblastic lines (MG63 and Saos-2), and their regulation by vitamin D 3 and dexamethasone has been demonstrated (10).
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ONE FORMATION occurs mostly during embryonic development and postnatal growth, but is also important in adults for subsequent bone remodeling to maintain calcium homeostasis and for adaptation to physical forces. Bone formation requires recruitment, proliferation, and differentiation of osteoprogenitor cells (1, 2) . Very little is known about the putative role of PRL with respect to bone cells and bone metabolism. Lactation in humans and mammals is associated with a vitamin D-induced maternal boneresorptive state, and it has also been suggested that PRL might induce the release of a bone-resorptive agent. Many clinical studies have reported a possible role for PRL in bone during pregnancy, lactation, or hyperprolactinemia, but other hormonal parameters could also be implicated, and no definitive results have been published (3) (4) (5) (6) . A direct demonstration of PRL receptor protein expression in bone cells is lacking, and the putative role of PRL in bone remains speculative. Recently, studies on PRL receptor expression in human, mouse, and rat fetal tissues have shown expression of PRL receptor messenger RNA (mRNA) and the appearance, during early fetal development of intense PRL receptor immunoreactivity in skeletal tissues, including long bones, vertebrae, and ribs (7) (8) (9) . Also, PRL receptor transcripts were detected in two human osteoblastic lines (MG63 and Saos-2), and their regulation by vitamin D 3 and dexamethasone has been demonstrated (10) .
PRL is synthesized and secreted by lactotrophic cells of the anterior pituitary gland of all vertebrates and by various extrapituitary sites including decidual cells of the placenta (11, 12) . PRL is mainly involved in actions such as induction and maintenance of lactation, reproduction, osmoregulation, and immunomodulation. However, this hormone has been shown to have multiple functions in various vertebrate species, including actions resembling those of a growth factor (12) . The PRL receptor is a single chain protein with only one transmembrane domain, belonging to the class I cytokine receptor superfamily. The activation of the PRL receptor occurs by ligand-induced homodimerization (13, 14) . In the mouse, the PRL receptor is expressed as three short forms (S1-PRLR, S2-PRLR, and S3-PRLR) and one long (L-PRLR) form, differing in the length and sequence of their cytoplasmic tails due to alternative splicing of a single PRL receptor gene (15) (16) (17) . The long and short receptor forms share iden-tical extracellular, transmembrane, and membrane proximal cytoplasmic domain sequences, but diverge in their carboxyl-terminal cytoplasmic sequences (15, 18) . The different cytoplasmic domains of these receptor forms may connect to distinct signaling pathways. Although both forms of the PRL receptor are dimerized by the binding of a single molecule of PRL to activate the tyrosine kinase Jak2 and can stimulate cell growth, only the long form of the receptor leads to activation of the transcription factor STAT5 (signal transducer and activator of transcription-5) and initiates milk protein gene transcription (19 -21) . In addition, PRL receptors are the targets of at least three hormones in mouse: PRL, placental lactogen I (PL-I), and PL-II (14, 22) .
In our laboratory, mice carrying a germline null mutation of the PRL receptor have been produced by gene targeting in embryonic stem cells (16) . In this knockout model, exon 5 of the gene encoding the PRL receptor was replaced with neomycin resistance gene cassette, resulting in a PRL receptor transcript deleted of 169 bp (size of exon 5) and, if translated, would generate a very short peptide unable to bind PRL. We have previously observed in heterozygous females the failure of mammary development and lactation after the first pregnancy and in PRL receptor-deficient (Ϫ/Ϫ) female mice complete sterility due to multiple causes, including failure of blastocyst implantation (16) . We have also identified altered maternal behavior in Ϫ/Ϫ animals (23). This mouse model has been used here to examine the putative effects of PRL in bone metabolism.
Materials and Methods

Mouse care
Animals care was in accordance with institutional guideslines. Mice were kept on a 12-h light, 12-h dark cycle (0700 -1900 h). Temperature was maintained at 24 C, and food and water were provided ad libitum. Heterozygous mutants (129Sv/C57BL/6) were bred to produce Ϫ/Ϫ, ϩ/Ϫ, and ϩ/ϩ animals. Pups were genotyped by PCR amplification of the NEO gene using specific primers previously described (16) .
Cell culture
Osteoblasts from calvaria were prepared and characterized as previously described (23a). Briefly, neonatal mouse calvaria were dissected free from adherent soft tissue, washed in PBS, and sequentially digested with 0.2% dispase (Boehringer Mannheim) and 0.1% collagenase (Sigma Chemical Co., L'Isle d'Abeau, France; five times for 15 min each time). Cells released by the last three enzymatic digestions were washed and grown in ␣MEM (Sigma Chemical Co.) containing 10% FBS and antibiotics.
PRL receptor ϩ/ϩ and PRL receptor Ϫ/Ϫ osteoclast-like cells were obtained from cocultures of wild-type osteoblastic cells and bone marrow cells from either PRL receptor-deficient mice or their wild-type littermates in the presence of 10 nm 1␣,25-dihydroxyvitamin D 3 (Hoechst Marion Roussel, Inc., Romainville, France) for 5 days. Osteoclast-like cells were purified by 0.1% (type 1a) collagenase (Sigma Chemical Co.) and 0.2% dispase (Boehringer Mannheim) treatment (24) . All cultures were maintained at 37 C in a humidified atmosphere of 5% CO 2 .
RNA extraction and RT-PCR analysis
Total cellular RNA was extracted as previously described (25) . First strand complementary DNA was synthesized from 1 g total RNA using 200 U Moloney murine leukemia virus reverse transcriptase (RT; Promega Corp., Madison, WI) for 2 h at 37 C after oligo(deoxythymidine) priming (250 ng). One microliter of the RT product was submitted to PCR for amplification of mPRL receptor sequences. The reaction mixture (50 l) contained 25 pmol of each primer for PRL receptor, 0.2 mm deoxy-NTPs, 50 mm KCl, 2 mm MgCl 2 , and 1 U Taq DNA polymerase. For PCR of different PRL receptor transcripts, amplification was performed using the Gem Amply PCR System 2400 (Perkin Elmer, Norwalk, CT) with the following profiles: 94 C for 5 min for 1 cycle; 94 C for 30 sec, 67 C for 1 min, and 72 C for 1.5 min for 30 cycles; and 72 C for 5 min for 1 cycle. For PCR performed with osteoclast-like cell mRNA extracts, amplification was performed with the following profiles: 94 C for 5 min for 1 cycle; 94 C for 45 sec, 62 C for 1 min, and 72 C for 45 sec for 35 cycles; and 72 C for 5 min for 1 cycle. Amplification products were resolved on 1% agarose gels. The specificity of the reaction was confirmed by Southern transfer onto Hybond N ϩ membranes (Amersham) and hybridization with a 32 P-labeled specific oligonucleotide.
Oligonucleotide probes
Specific probes, complementary to different forms of PRL receptor mRNAs, were used as follows (synthesis by Genentech, Inc., Eurogentec, Seraino, Belgium). Wsm (5Ј-CATGGATACTGGAGTAGATGGGGC-3Ј) is complementary to the extracellular domain of the mouse PRL receptor. S1 (5Ј-CAACTGGAGAATAGAACACCAGAG-3Ј), S2 (5Ј-CTTG-TATTTGCTTGGAGAGCCAGT-3Ј), and S3 (5Ј-TTCAAGTTGCTCTTT-GTTGTGAAC-3Ј) are oligonucleotides specific to the cytoplasmic domains of the three different short forms of the mPRL receptor deduced from sequences previously published (18) . mLF2 (5Ј-TTGCACAGC-CACTTCTTCCTCTCC-3Ј) is complementary to the 529-to 553-bp sequence of the cytoplasmic domain of the long form of the mPRL receptor (15) . The sequence of the oligonucleotide used for Southern analysis is 5Ј-GATGACAGCAGAGAGAACGGCACA-3Ј. For PCR performed with osteoclast-like cell mRNA extracts, two oligonucleotides derived from exons 2 and 7 were used: exon 2 primer, 5Ј-TGAGCATCGCAG ATGTTTTGCAC-3Ј; and exon 7 primer, 5Ј-TTGATGACCTGTGAAGT-GGAT-3Ј. Oligonucleotides derived from exons 4 and 5 were used to identify the resulting bands by Southern analysis (exon 4 probe, 5Ј-GGTCAGATGGAGGACTCCCCACCA-3Ј; and exon 5 probe, 5Ј-GAGAAAAAC ACCTATGAATGTC-3Ј).
Western blot analysis
Total osteoblast proteins were solubilized in Tris-HCl (pH 7.4) and 10 mm MgCl 2 -0.5% Triton X-100 at 4 C for 1 h. Osteoblasts from four petri dishes (100 mm) were washed three times with cold PBS, scraped from plates, and collected into PBS on ice. Cells were pelleted and resuspended in 1.2 ml lysis buffer [50 mm Tris-HCl (pH 8.0), 150 mm NaCl, 5 mm MgCl 2 , 1% Triton X-100, 0,5% sodium deoxycholate, 0.1% SDS, 0.5 mm phenylmethylsulfonylfluoride, 10 g/ml of leupeptin, 10 g/ml aprotinin, and 10 g/ml pepstatin] at 4 C on a wheel stirrer for 30 min. The extracts were centrifuged, and the supernatant was incubated overnight with 2 g U5-specific mouse monoclonal antibody against the PRL receptor (26) before the addition of goat antimouse IgG antibodies immobilized on agarose beads. The beads were collected by centrifugation and washed three times in Tris-HCl (pH 7.4), 10 mm MgCl 2 , and Triton X-100 before denaturation by boiling 5 min in 3% SDS and 5% ␤-mercaptoethanol in 12 mm Tris-HCl (pH 6.8). Samples were electrophorised and electrotransferred to enhanced chemiluminescence (ECL) nylon membranes. Membranes were incubated with 2 g/ml U5 antibody in 50 mm Tris-HCl (pH 7.5), 200 mm NaCl, 0.05% Tween-20, and 1% BSA (AB) for 2 h at room temperature with gentle rocking. Membranes were washed three times for 15 min each time in 50 ml 50 mm Tris-HCl (pH 7.5), 200 mm NaCl, and 0.05% Tween-20 (WB) before incubation with goat antimouse IgG linked to peroxidase in AB for 1 h and washed four times for 20 min each time in 50 ml WB. Bands were visualized using x-ray film and the ECL chemiluminescence kit.
Histological examination of calvaria
Calvaria from E18.5 embryos were fixed in 4% formalin solution and processed for conventional histology. Calvaria were embedded in paraffin examined on 20 noncontiguous 5-m-thick sections colored with hematoxylin-eosin-safran, or von Kossa's stain.
Histomorphometry of long bone
Double labeling was performed as described previously (27) . The first calcein injection (2 mg/kg BW) was followed by the same dose of calcein 7 days later. Eight-week-old animals were killed 2 days after the second injection, and their tibia and femora were dissected and fixed in PBSbuffered formaldehyde (pH 7.0). After embedding in methyl-methacrylate, and sectioning at 10 m, a blind analysis of the unstained samples was conducted under fluorescent light. Measurements of the mineral apposition rate and the bone formation rate and quantification of the percentage of mineralizing surface were performed in wild-type (ϩ/ϩ) and mutant (Ϫ/Ϫ) littermates. Histomorphometric parameters, such as osteoid tissue, bone volume, osteoblast surface, and osteoclast number, were analyzed following the recommended nomenclature (28) . These parameters were determined in an area of 300 m in length from the chondro-osseous junction to the diaphysis surrounded by cortical bone on both sides.
Bone mass measurements by dual energy x-ray absorptiometry
Techniques measuring bone mineral density (BMD) and bone mineral content (BMC) using energy x-ray absorptiometry with Hologic QDR 1000 instruments (Waltham, MA) were adapted for application in the mouse. An ultra high resolution mode was used with a collimator 0.09 cm in diameter as previously described (29) . Histomorphometric parameters follow the recommended nomenclature (28) .
Serum mineral analysis
Serum calcium, phosphate, and magnesium levels were measured in samples from individual males or females (4 months old) by absorption spectrophotometry. All measurements were assayed on a Hitachi 400 automatic analyzer (Hitachi, Tokyo, Japan). Calcium levels were confirmed and validated by simultaneous serum albumin measurements.
Hormone concentration determinations
Estradiol, progesterone, and testosterone were measured in individual serum samples from 4-month-old animals using human RIA kits (Immunotech, Paris, France; reference no. 1663, 1188, and 1087, respectively). Serum levels of estradiol and progesterone were measured on the morning of estrous. The estrous cycle was confirmed by vaginal smears. The serum concentration of PTH was measured in individual serum samples of 4-month-old animals using a rat PTH immunoradiometric assay kit (Nichols Institute Diagnostics, Avon, France).
Results
Delay of ossification in calvaria of knockout embryos (18.5 days)
A systemic histological evaluation of embryos from ϩ/ϩ and Ϫ/Ϫ animals lead us to detect a delay in bone ossification in calvaria. Figure 1 shows coronal sections of calvaria of 18.5-day-old ϩ/ϩ and Ϫ/Ϫ embryos (total n ϭ 3; three different litters). Clearly, less ossified tissue is seen in sections of Ϫ/Ϫ calvaria colored with either hematoxylin-eosinsafran (A and B) or von Kossa' s stain (C and D). This reduced calcification did not affect postnatal cranial development.
Histomorphometric analysis of bone formation
To further analyze bone metabolism, dynamic parameters of bone remodeling were measured by histomorphometry after double labeling with calcein, a marker of newly forming bone. In general, no difference was seen between males and females, and data were combined for both genders. Dual calcein labeling in postpubescent (8-week-old) ϩ/ϩ and ϩ/Ϫ mice features two fluorescent bands that confirm normal bone formation in trabecular and cortical bone of control animals. In contrast, results obtained with Ϫ/Ϫ mice clearly show less separation of the two fluorescent bands compared with ϩ/ϩ and ϩ/Ϫ mice (Fig. 2 , A-D; data not shown for heterozygotes). When results were tabulated for four (ϩ/ϩ) and six (Ϫ/Ϫ) mice per group from three litters, trabecular and cortical mineral apposition rates were significantly decreased in long bones (tibiae and femora) of PRL receptor Ϫ/Ϫ mice. On the other hand, there was no modification in mineralizing surface between ϩ/ϩ and Ϫ/Ϫ mice (Table 1) . Consequently, there was a 60% decrease in the bone formation rate in knockout animals compared with that in wildtype littermates, indicating that the lack of PRL receptor leads to a profound slowing down of bone formation (Table  1) . Interestingly, considering the decrease in mineral apposition rates and bone formation rates, osteoblast surface, which is a reliable indicator of the number of osteoblasts and osteoid surface, was not significantly diminished in the knockout animals (Table 1 ). There was also no significant difference between the number of osteoclasts and the bone volume in Ϫ/Ϫ mice compared with those in wild-type controls. Thus, the bone formation rate is decreased in PRL knockout animals, whereas the number of resorbing cells is maintained, a situation that could lead to a diminished bone mass. The bone alterations observed could be due to a problem in osteoblast activity rather than a decrease in osteoblast number. This is in accordance with the unaltered mineralizing surface. No radiographic evidence of skeletal malformation was seen in adult Ϫ/Ϫ mice at 6 and 10 weeks of age. In addition, radiographic analysis of long bones of 6-, 9-, and 16-week-old wild-type and knockout animals revealed no difference in the overall size of Ϫ/Ϫ mice.
Analysis of BMD
To determine whether the KO animals were indeed osteopenic, measurements of BMD and BMC were performed by dual energy x-ray absorptiometry with a Hologic QDR 1000 instrument adapted for application to mice. Validation of this methodology has been performed by comparison with the method of chemical analysis of calcium ashes (29) . To account for possible differences in the local proportion of trabecular and cortical bone, the tibia was divided into three equal regions. The proximal tibia corresponds to the region containing the largest proportion of trabecular bone, and the midshaft was essentially formed by cortical bone. At 4 months of age, knockout male and female mice had a significantly lower bone mass than their littermate controls, as evaluated by a reduction in BMD and BMC (Fig. 3, A and B) .
Serum mineral measurements
As the animals showed an alteration in BMC, it seemed of interest to measure serum calcium and phosphate levels. Total serum calcium, magnesium, and phosphorus were determined by spectrophotometric measurements. Analysis of serum from ϩ/ϩ and Ϫ/Ϫ 4-month-old animals indicated that knockout mice have a significant increase in serum calcium, with no statistically significant changes in phosphorus or magnesium levels, although a trend for increased magnesium levels was observed in knockout mice (Fig. 4) . The increase in serum calcium levels has been validated by simultaneous albumin measurements. Levels of serum albumin were not modified in knockout mice compared with those in wild-type animals [25.83 Ϯ 2.93 g/liter (n ϭ 6) vs. 25.50 Ϯ 2.35 g/liter (n ϭ 6) for wild-type and knockout mice, respectively]. Urinary calcium was measured and standardized with creatinine levels. No modifications were observed [3.61 Ϯ 0.49 mmol/liter (n ϭ 10) vs. 3.42 Ϯ 0.29 mmol/liter (n ϭ 10) for wild-type and knockout mice, respectively].
Hormone determinations
We measured serum estradiol and progesterone levels in adult females at estrus. They are included in Table 2 along with testosterone levels in males and PTH levels in males and females. Major modifications were seen in calciotropic and some steroid hormones. Homozygous mutants exhibited an elevation in serum PTH levels. The levels of estradiol and progesterone in females were clearly decreased; this was especially evident for progesterone. These was no evident modification in testosterone levels in males. Finally, the serum PRL level was greatly increased (40-fold) in PRL receptor Ϫ/Ϫ males and females (data not shown). Heterozygous mice were indistinguishable from their wild-type littermates with respect to hormone and bone status.
Expression of PRL receptor transcripts in wild-type murine osteoblasts
Expression of PRL receptor transcripts in murine bone cells was analyzed using RT-PCR. Using specific primers for the three short forms previously described in the mouse liver, we found the appropriate PCR product (246 bp) for two of the three short forms (S1 and S3) in murine osteoblasts. A transcript encoding the long form of mouse PRL receptor (777 bp) was also detected in murine osteoblasts using the same forward primer and a reverse primer in the specific cytoplasmic domain (Fig. 5A) . The specificity of the PCR products was confirmed by Southern blot analysis with a common transmembrane (exon 8) probe (Fig. 5B) . 
Expression of PRL receptor protein in wild-type murine osteoblasts
Comparative Western blot analysis of immunoprecipitated proteins from primary cultures of ϩ/ϩ or Ϫ/Ϫ osteoblasts revealed that only the long form of the receptor was detected in wild-type cells despite the presence of S1 and S3 transcripts (Fig. 5C ). We used monoclonal antibody U5 to the rat PRL receptor (26) , which recognizes an extracellular epitope of the receptor located in a region of the protein encoded by gene sequences after the exon 5 deletion introduced in Ϫ/Ϫ mice. Positive controls were performed using human breast cancer cells (T-47D; long form), rat liver microsomes (short form; Fig. 5C ), and 293 cells expressing short, long, and intermediate forms of the rat PRL receptor (Fig. 5D) .
Lack of expression of PRL receptor transcripts in wild-type murine osteoclast-like cells
To determine whether PRL receptor mRNA was also expressed in osteoclasts, osteoclast-like cells were prepared by coculturing primary cultured osteoblasts from PRL receptor knockout mice with bone marrow cells from wild-type (ϩ/ϩ) mice, or conversely, in the presence of 1,25-dihydroxyvitamin D 3 (24) . RNA from osteoclast-like cells was reverse transcribed, and the resulting complementary DNA was used for PCR amplification of a region spanning the exon 5 deletion, by primers located in exons 2 and 7 (Fig. 6A) . After ϩ/ϩ osteoclast-like cells were produced by coculture with Values are the mean Ϯ SEM (n ϭ 6 for ϩ/ϩ; n ϭ 6 for Ϫ/Ϫ). a Statistically significant difference between wild-type (ϩ/ϩ) and PRL receptor-deficient (Ϫ/Ϫ) groups (P Ͻ 0.01), evaluated by ANOVA.
osteoblasts from Ϫ/Ϫ animals, and RT-PCR was performed on osteoclast-like cells mRNA, only a single band was observed, the size of which corresponded to the 169-bp deletion of exon 5, as expected for a Ϫ/Ϫ transcript (Fig. 6B) . Internal 20-mer probes derived from exons 4 and 5 were used to identify the resulting bands by Southern analysis. These results indicate that PRL receptor transcripts are totally absent from murine osteoclast-like cells (or other minority cells derived from precursor bone marrow cells after coculture and purification), and that osteoblasts represent the only potential target of PRL in bone (Fig. 6, C and D) .
Discussion
Our results suggest that bone formation slows in the absence of the PRL receptor, leading to a decreased bone mass. Although the effect of PRL could be direct and/or indirect, it is noteworthy that murine osteoblasts, but not osteoclasts, express a receptor for this hormone. No difference was detected between males and females, except in serum testosterone, estradiol, and progesterone levels. The role of the PRL receptor in bone metabolism and the physiological mechanisms by which PRL regulates bone remodeling remain to be determined, but the PRL receptor knockout mouse is an unexpected but useful model to study bone formation.
Bone status in PRL receptor knockout mice
Histomorphometric observations on embryonic calvaria and the reduction in bone formation rates without a comparable decrease in osteoblast or osteoid surface in adults suggest that functional activity, rather than bone-forming cell populations, is altered. Evaluations of the functional activities of osteoblasts isolated from knockout animals are in progress. In addition, BMD and BMC were significantly reduced in proximal and total tibia in PRL receptordeficient mice compared with those in control mice, confirming that PRL receptor knockout mice are osteopenic. These in vivo observations suggest the implication of PRL in bone metabolism sometimes evoked in physiological studies involving PRL. In the last decade, clinical studies have attempted to correlate plasma PRL levels with osteopenia observed during lactation, weaning, or postmenopausal states (3, 6, 30) .
Prolonged administration of PRL decreased calcium excretion in mature rats and increased bone formation and tibia calcium content in growing rats (31) . PRL enhanced calcium turnover in both compact and trabecular bones of mature rats. Young rats responded to PRL by increasing the rate of mineral deposit, whereas weaned rats increased calcium release (32, 33) . The analysis of bone metabolic parameters, bone turnover, bone formation, and bone resorption showed an increase during hyperprolactinemia.
During lactation and postweaning, BMD and markers of bone remodeling are modified in women (3, 6) . The skeletal changes occurring during lactation can be quite dramatic in some species. In the first reproductive cycle of rats, there can be a substantial loss of metaphyseal cancellous bone, particularly in long bones, with a bone turnover rate considerably elevated (34) . There are also changes in cortical bone during the reproductive cycle in rats, including periosteal and endocortical expansion, with a significant increase in the medullar cavity area (34) .
In all of these studies, hypogonadism associated with hyperprolactinemia has been evoked to explain the final decrease in BMC (4, 35) . The main mechanism of BMD loss in these cases probably involved in part hypoestrogenemia, but a direct effect of PRL cannot be excluded. On this point, our in vitro results are in agreement with the hypothesis of a direct role of PRL in bone metabolism.
PRL receptor expression in murine bone
The presence of short and long forms of PRL receptor mRNAs in osteoblasts confirms the potential of a direct action of PRL on murine osteoblasts but not on osteoclasts. The presence of PRL receptor transcripts in two human osteoblastic lines (MG63 and Saos-2) and the regulation of these transcripts by vitamin D 3 and dexamethasone have also recently been reported (10) . In addition, PRL receptor mRNA and protein levels have been shown to increase during gestation in a number of fetal rat bone tissues (7) . The presence of PRL receptor in such tissues and more specifically in osteoblasts is consistent with our results.
The expression of the long form of the PRL receptor protein in murine osteoblasts and the demonstration of a negative effect on bone metabolism resulting from the null mutation of the PRL receptor strongly indicate that the PRL receptor plays a role in bone formation. The long form of the receptor appears to be the active form in bone and has been shown previously to be functionally active in terms of transcription of PRL-stimulated genes (13, 14) . Interestingly, the short form of the PRL receptor protein could not be detected in normal murine osteoblasts under our experimental conditions. This absence could be due to the relatively low level of short form transcript or the reduced stability of this mRNA, but we cannot exclude the possibility of short form expression only under certain physiological conditions, whereas its role remains unknown for now.
PRL receptors have been localized in maturing chondrocytes, tooth buds, and developing vertebrae (9) . The cellular distribution and developmental expression of the PRL receptor were examined by in situ hybridization, immunohistochemistry, and radioligand binding. The studies of PRL receptor expression in human and rat fetal tissues (respectively, between 7.5-14.5 weeks and 12.5-20.5 days of age) show the appearance in early fetal development of intense PRL receptor immunoreactivity in tissues, including long bones, vertebrae, and ribs (7-9). Thus, the possible role of the PRL receptor in embryonic bone development is potentially of importance in almost all species (including humans) in view of the fact that the PRL receptor is also a target of placental lactogens. From approximately embryonic day 8.5 until birth in the mouse, during the period of substantial fetal growth and development, it is possible that placental lactogen, first PL-I and then PL-II, functionally activate PRL receptors (9, 22) . Thus, even in the absence of pituitary PRL, PRL receptors could be involved in bone formation. A recent paper describing inactivation of the PRL gene did not specifically report any alteration in bone development (36) . Either more detailed studies of these mice will be required or perhaps PLs can compensate for the lack of PRL in these mice. We propose that the PRL receptor plays a role in fetal bone development with consequences on bone status in adults. Values are the mean Ϯ SEM (10 ϩ/ϩ females and 10 Ϫ/Ϫ females for estradiol and progesterone assays, 10 ϩ/ϩ males and 10 Ϫ/Ϫ males for testosterone assay, and 5 ϩ/ϩ and 5 Ϫ/Ϫ of each gender for PTH assay). Statistically significant differences between wild-type (ϩ/ϩ) and PRL receptor-deficient (Ϫ/Ϫ) mice, evaluated by ANOVA, are indicated.
a P Ͻ 0.01. b P Ͻ 0.05.
Hormonal status of PRL receptor knockout mice
The increase in serum calcium levels observed in knockout animals remains obscure, but it is well known that mineral homeostasis is under the control of hormones such as PTH, estradiol, or calcitriol, which have been suggested to be directly or indirectly involved with PRL metabolism (5, 37, 38) . All mineral abnormalities could be explained by estrogen and progesterone deficiency or/and the high level of PTH. This high level of PTH in knockout mice (males or females) could also explain the calcium and bone abnormalities. In addition, the active form of 1,25-dihydroxyvitamin D is PRL regulated, so it will be interesting in the future to measure the level of 1,25-hydroxyvitamin D. In summary, the hormonal status of the knockout mice are perturbed, resulting in several potential consequences, not only for bone formation but also for reproductive status and behavior.
Others groups have demonstrated the importance of hormones such as estradiol, GH, or progesterone directly on bone cells or at least in bone metabolism (39 -41) . Despite the possible direct effect of PRL in osteoblasts demonstrated in the present report, we cannot rule out a potential indirect systemic effect of PRL via interactions with the regulation of hormones implicated in bone metabolism. The PRL receptor knockout mouse may be a useful model to study such actions. A number of other phenotypes have been reported in this model: sterility, due in part to a failure of blastocyst implantation, and modification of maternal behavior (16, 23 ). Our results demonstrate that the hormonal status of the knockout mice is clearly altered, with several potential consequences on bone. Although it is difficult to make any general interpretations, both the potential systemic effects of hormonal alterations and the potential direct effects due to the absence of PRL receptor in knockout mice must be considered. In vitro approaches with normal and PRL receptordeficient osteoblasts should allow us to better understand the role of PRL in bone and to separate direct and indirect actions of the PRL receptor. The balance between PRL and estradiol, progesterone, and PTH will be important to better understand the mineral status of the animals and the regulation of the total mineral stock. The potential hormonal dysregulation in this mouse model, especially concerning estradiol and/or progesterone, represents one of the interesting questions to be addressed.
It is noteworthy that there is convergence of certain genes regulating bone remodeling, linked to tight attachment of osteoclasts to the bone matrix, and oocyte implantation in the endometrial matrix. After fecondation, progesterone stimulates calcitonin (42), insulin-like growth factor I (43), and basic fibroblast growth factor (39) secretion in the uterus. These proteins are also implicated in bone metabolism. Moreover, some researchers have observed a local synthesis of PTH and integrins in the implantation area of the oocyte (44, 45) . The reproductive dysfunctions seen in PRL receptordeficient mice could open new fields of investigation concerning progesterone and hormonal regulation in general and interactions between cells and the extracellular matrix in bone metabolism in particular.
Secondly, we must evoke the possible interactions between PRL and estradiol and their effects on bone turnover in PRL receptor-deficient mice. Recently, it has been reported that alterations in maternal estrogen levels during pregnancy can influence early phases of fetal bone development and subsequently result in permanent changes in the skeleton (46) . One approach would be to ovariectomize PRL receptor knockout mice and evaluate a change in bone formation in the context of an estrogen deficiency.
Finally, PTH-related peptide (PTH-rP) was recently shown to be expressed in human mammary tissue, and elevated circulating PTH-rP levels as well as concomitant hypercalcemia have been described during lactation (5) . Some data support the hypothesis that PTH-rP is an alternative mechanism associated with bone loss and recovery during and subsequent to lactation with associated low serum estradiol levels (5). Overexpression of PTH-rP in myoepithelial cells in mammary glands of transgenic mice has been reported to result in a form of mammary hypoplasia characterized by a profound defect in branching morphogenesis of the developing mammary duct system (47) . PTH-rP, which is a mature product of mammary epithelial and myoepithelial cells, may participate in normal mammary development, perhaps as a locally secreted growth inhibitor. These data support the hypothesis of an interaction between PRL and PTH-rP during lactation and their putative association in bone loss (38) . Despite this, an increase in PTH or/and PTH-rP could explain the increase in serum calcium, but not the decrease in bone formation.
Conclusions
Our data suggest that the bone alterations observed in PRL receptor knockout mice represent a delay in bone formation, leading to minor osteopenia. Although there have been some reports suggesting that PRL might play a role in bone development, the results described in the present manuscript are the first to clearly demonstrate that the presence of a lactogen receptor could be important for normal bone remodeling. On the basis of these results, it is possible to define new axes of investigation concerning the effects of PRL and its hormonal consequence on bone metabolism. In vitro studies also represent a means to analyze the direct effects of PRL on bone, in particular signal transduction and biological responses in osteoblasts. These studies should to be of broad general interest to basic scientists and clinicians, because they help in the understanding of bone disorders observed during pregnancy, lactation, and under certain pathological conditions such as hyperprolactinemia. 
